Showing results (141-150 of 228) with videos related to

Sort By:
Pageof 23
Blood Advances|May 10, 2023
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project NetworkGreg Hapgood, Monica Civallero, Yana Stepanishyna, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Haematologica|March 31, 2018
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell ProjectMonica Bellei, Francine M Foss, Andrei R Shustov, et al.
Aesthetic Surgery Journal|May 31, 2022
2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCLFabio Santanelli di Pompeo, Mark W Clemens, Michael Atlan, et al.
Dermatology and Therapy|November 24, 2021
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and ManagementAmy C M Musiek, Kerri E Rieger, Martine Bagot, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 1, 2021
Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional ExperienceN Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 19, 2021
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional ExperienceN Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.
Pageof 23